Liver Transplantation, Liver Disease, Immunosuppression
Conditions
Keywords
liver transplant
Brief summary
The purpose of this study is to compare kidney function, long term patient and graft survival, and incidence of acute rejection in liver transplant recipients between one group receiving thymoglobulin induction and delayed initiation of tacrolimus and another group of liver transplant recipients having immediate administration of tacrolimus without any induction immunosuppression.
Detailed description
Renal insufficiency following liver transplantation in adult recipients is a major cause of morbidity and a major contributor to mortality. One of the key factors contributing to this renal dysfunction is the use of calcineurin inhibitors. There is some evidence to suggest that the first 7-10 days following liver transplantation are crucial in terms of renal function and the ability to avoid the use of nephrotoxic agents such as calcineurin inhibitors may have a significant impact on long-term outcome.
Interventions
1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
DRUGtacrolimus
Tacrolimus will be administered orally on post op day #1 as per standard of care.
Sponsors
Genzyme, a Sanofi Company
University of Nebraska
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary liver transplant recipient with Model for End Stage Liver Disease (MELD) criteria documentation * Over 18 years of age * Signed informed consent form * if female of childbearing potential: Must not be lactating Must have negative serum pregnancy test on study day 0 Must have agreed on a reliable and acceptable form of contraception during the study * sexually active males must be practicing an acceptable form of contraception
Exclusion criteria
* Multiple organ transplants * Prior solid organ or bone marrow transplant recipients * Fulminant hepatic failure * Status 1 transplants * Liver transplant candidates with greater than 6 weeks of dialysis * Patients who in the opinion of the Investigator are not eligible for thymo induction at the time of transplant * Recipients of investigational therapy within 90 days prior to transplant * Know contraindication to administration of rabbit anti-thymocyte globulin * Patients whose medical condition is such that the physician feels it would not be in their best interest to participate in the study * Patients who are unwilling to have a Glofil nuclear medicine scan at specified time points * History of malignancy within 5 years with the exception of: * Adequately treated localized squamous or basal cell carcinoma of the skin without evidence of recurrence, and /or * Hepatocellular carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of renal function via Glo-Fil nuclear medicine scan and laboratory parameters | Post operative day #1, month 6 and month 12 |
Secondary
| Measure | Time frame |
|---|---|
| patient and graft survival, incidence of acute rejection, incidence of active CMV disease, incidence of other infections, any adverse events or serious adverse events associated with the use of thymo induction therapy | post op days 1-6, months 3,6, 9, and 12 |
Countries
United States
Outcome results
None listed